Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Other Non Operating Income (2021 - 2026)

MoonLake Immunotherapeutics' Other Non Operating Income history spans 6 years, with the latest figure at $3.2 million for Q1 2026.

  • Quarterly Other Non Operating Income fell 54.8% to $3.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $18.5 million through Mar 2026, down 20.72% year-over-year, with the annual reading at $22.4 million for FY2025, 1.1% up from the prior year.
  • Other Non Operating Income came in at $3.2 million for Q1 2026, down from $4.4 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $7.2 million in Q4 2023 to a low of $37593.0 in Q3 2022.
  • The 5-year median for Other Non Operating Income is $3.2 million (2024), against an average of $3.4 million.
  • Year-over-year, Other Non Operating Income surged 6584.92% in 2022 and then crashed 55.1% in 2024.
  • MoonLake Immunotherapeutics' Other Non Operating Income stood at $239505.0 in 2022, then surged by 2900.12% to $7.2 million in 2023, then plummeted by 55.1% to $3.2 million in 2024, then surged by 37.69% to $4.4 million in 2025, then fell by 27.78% to $3.2 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Other Non Operating Income are $3.2 million (Q1 2026), $4.4 million (Q4 2025), and $4.1 million (Q3 2025).